Treatment of neuropathic pain is challenging. Pregabalin and duloxetine are used as first-line therapy. Various international guidelines recommend a combination of first-line agents for the management of neuropathic pain. The objective of this study was to evaluate the efficacy and safety of a fixed-dose combination (FDC) of low-dose pregabalin and duloxetine compared to pregabalin monotherapy at week 7 in patients with moderate to severe neuropathic pain. This was a phase 3, randomized, double-blind, double-dummy parallel-group non-inferiority study conducted at 17 sites across India. Three hundred and twenty-eight adult patients with moderate to severe neuropathic pain were randomized in a ratio of 1:1 to receive a FDC of pregabalin and duloxetine or pregabalin monotherapy for 7 weeks followed by a one-week follow-up. The pregabalin-duloxetine combination was initiated at 50 plus 20 mg per day and gradually titrated to a maximum of 75mg plus 30mg twice daily. Pregabalin was initiated at 75mg/day and gradually titrated to a maximum of 150mg twice daily. The main efficacy outcome was a mean change in pain intensity at the end of 7 weeks. Two hundred and ninety-eight patients completed the study, 148 in the pregabalin-duloxetine group and 150 in the pregabalin group. The mean change in daily pain at 7 weeks was as follows: -4.49 with FDC and -4.66 with pregabalin (p<0.0001). The non-inferiority of a low-dose FDC compared to pregabalin monotherapy was demonstrated at the end of the study. The incidence of dizziness and somnolence was comparable between both treatments. A higher frequency of peripheral oedema was observed with pregabalin monotherapy than in the FDC group (p>0.05). A FDC of low doses of pregabalin and duloxetine and high dose of pregabalin monotherapy achieved similar analgesia with dizziness, and somnolence as the most frequent adverse event. CTRI/2020/09/027555.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11016171 | PMC |
| http://dx.doi.org/10.12688/f1000research.130345.1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pain Management in Brugada Syndrome: A Case Report and Review.
A A Pract
January 2025
Division of Anaesthesiology and Perioperative Medicine, Department of Pain Medicine, Singapore General Hospital, Singapore.
Article Synopsis
- Brugada syndrome is a rare condition that elevates the risk of serious heart arrhythmias, with limited guidance on pain management for these patients.
- A case study of a young woman with the syndrome highlights the use of ropivacaine peripheral nerve infusion and intravenous ketamine for managing her acute-on-chronic pain in the left upper limb.
- The approach included a multimodal analgesia strategy with neuropathic agents and opioids, aiming to improve safe pain management practices for those with Brugada syndrome.
Pain Management in Fibromyalgia: Evaluating the Roles of Pregabalin, Duloxetine, and Milnacipran.
Cureus
December 2024
Family Medicine, Holy Family Hospital, Rawalpindi, PAK.
Introduction Fibromyalgia is a chronic pain disorder characterized by widespread pain, fatigue, and sleep disturbances. The purpose of this study was to compare how well duloxetine, pregabalin, and milnacipran worked for fibromyalgia patients in terms of pain management, quality of life, and sleep quality. Methodology A prospective cohort research study with 193 fibromyalgia patients was carried out at the Abbas Institute of Medical Sciences, Muzaffarabad, Pakistan.
View Article and Find Full Text PDFEffectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.
Rheumatology (Oxford)
December 2024
Division of Preventive Medicine, Department of Medicine, University of Alberta, Edmonton AB, Canada.
Objectives: To summarise and evaluate Cochrane reviews of pharmacological therapies for adults with fibromyalgia syndrome (FMS) pain.
Methods: Systematic search of Cochrane Database of Systematic Reviews to May 2024. Generic quality assessment used AMSTAR-2 criteria, validity checks of potentially critical factors in evaluation of analgesic efficacy, and assessment of susceptibility of results to publication bias.
Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.
Rheumatology (Oxford)
December 2024
Division of Preventive Medicine, Department of Medicine, University of Alberta, Edmonton AB, Canada.
Objectives: To summarise and evaluate Cochrane reviews of pharmacological therapies for adults with fibromyalgia syndrome (FMS) pain.
Methods: Systematic search of Cochrane Database of Systematic Reviews to May 2024. Generic quality assessment used AMSTAR-2 criteria, validity checks of potentially critical factors in evaluation of analgesic efficacy, and assessment of susceptibility of results to publication bias.
Comparative efficacy and safety of gabapentin, pregabalin, oxcarbazepine, and duloxetine in diabetic peripheral neuropathy: A network meta-analysis.
Perspect Clin Res
July 2024
Department of Pharmacology, Smt.NHL MMC, Ahmedabad, Gujarat, India.
Purpose: To conduct a network meta-analysis comparing the safety and efficacy of gabapentin (GBP), pregabalin (PGB), oxcarbazepine (OXC), and duloxetine (DLX) in treating diabetic peripheral neuropathy (DPN).
Materials And Methods: The study's eligibility criteria includee randomized controlled trials (RCTs) with a focus on DPN patients receiving GBP, PGB, DLX, or OXC versus placebo. Noncompliant trials with incomplete information and observational studies were excluded.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!